$MLAB Mesa Laboratories, Inc.BATS:MLABDillyDallyGallyMLAB is a $520M-market-cap maker of life-science quality-control tools across four divisions: Sterilization & Disinfection Control (SDC, 41% of FY26 revenue, biological/chemical indicators for sterilization validation — the crown-jewel, regulatory-driven, high-margin franchise), Biopharmaceutical Development (BPD, 20%, Gyrolab protein-analysis systems and PurePep peptide synthesizers), Calibration Solutions (CS, 21%, dialysis/gas-flow/torque calibration instruments), and Clinical Genomics (CG, 18%, MassARRAY genetic-analysis platform, heavily China-exposed). FY26 (ended 3/31/26) revenue was $249.1M, up 3.4% organically (1.2% core organic, ex-FX). The moat is real but narrow: SDC's biological indicators are consumables tied to regulatory-mandated sterilization validation in pharma/med-device manufacturing — sticky, recurring, high-margin (gross margin ~71-74% ex-FX). The other three divisions are weaker: BPD competes in a crowded bioprocessing-tools market and is now exposed to export controls on peptide-synthesis hardware; CS is a steady, low-growth calibration business; CG's genomics platform has seen China revenue collapse (-57% for FY26) as that market's growth engine reverses. This is a quality-core-plus-three-mediocre-segments story, not a uniform compounder.